PRENW · Prenetics Global Limited

The appointment of Brian J. Rosin as CFO of IM8 represents a strategic inflection point for Prenetics’ flagship consumer brand, signaling a deliberate shift toward institutionalized financial discipline amid hypergrowth. With IM8 projecting $190–$210 million in revenue for full-year 2026 — just its second year post-launch — and having already achieved $100 million in annualized recurring revenue within 11 months, the scale-up requires robust financial infrastructure, unit-economics rigor, and capital allocation expertise that Rosin’s background directly addresses. His prior roles as CFO at Wellbeam Consumer Health and its portfolio brands (TruSkin, BioTRUST, Eu Natural) demonstrate proven experience scaling digitally native, science-backed wellness businesses — a critical fit given IM8’s AI-native operating culture and premium positioning. Importantly, Rosin’s mandate explicitly includes investor relations support and financial strategy, suggesting enhanced transparency and governance expectations for IM8’s standalone performance. While the filing does not disclose compensation terms or transition timelines, the emphasis on his U.S. base and direct reporting line to CEO Danny Yeung underscores IM8’s operational autonomy and strategic priority within Prenetics’ broader health sciences platform. For investors, this executive hire mitigates execution risk associated with rapid international expansion and strengthens credibility around IM8’s path to durable, profitable category leadership.